Clinical Trial

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

Name: A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy — clinical trial record (NCT07633756)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Trial Details

NCT Number	NCT07633756
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Phase 1b, Open Label, REC-617, RB1-Negative, Leiomyosarcoma
Enrollment	15 participants
Start Date	2026-10-19
Primary Completion	2029-12-26 (estimated)
Study Completion	2031-12-26 (estimated)
Updated on ClinicalTrials.gov	2026-06-08